Advertisement

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer

  • Charles H. Weaver
  • Robert Birch
  • Lee S. Schwartzberg
  • William H. West
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 76)

Abstract

Carcinoma of the breast ends the life of nearly 50,000 women each year in the United States [1]. Refinements in surgery and radiation have improved cosmesis and local control but have failed to deal with the insidious systemic nature of this disease. Conventional dose adjuvant chemotherapy has also failed to impact national mortality figures [2]. At historically applied doses, adjuvant chemotherapy represents inadequate systemic therapy for a large proportion of patients.

Keywords

Breast Cancer Clin Oncol Metastatic Breast Cancer Peripheral Blood Stem Cell Autologous Bone Marrow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steele GD, Osteen RT, Winchester DP, Murphy GP, Menck HR: Clinical highlights from the National Cancer Database, 1994. CA Cancer J Clin 44:71–80, 1994.PubMedCrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71–85, 1992.Google Scholar
  3. 3.
    Frei EI, Canellos GP: Dose, a critical factor in cancer chemotherapy. Am J Med 69:585–599, 1986.CrossRefGoogle Scholar
  4. 4.
    Hrynik W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288, 1984.Google Scholar
  5. 5.
    Hryniuk WM: More is better. J Clin Oncol 6:1365–1367, 1988.PubMedGoogle Scholar
  6. 6.
    Frei EI, Cucchi GA, Rosowski A: Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158–2162, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Frei E, Antman K, Teicher B, Eder P, Schnipper L: Bone marrow autotransplantation for solid tumors: Prospects. J Clin Oncol 7:515–516, 1989.PubMedGoogle Scholar
  8. 8.
    Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weisenburger DD: High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74:1260–1265, 1989.PubMedGoogle Scholar
  9. 9.
    Phillip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosley A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkins’ lymphoma. N Engl J Med 316: 1493–1497, 1987.CrossRefGoogle Scholar
  10. 10.
    Santos, GW, Tutschka PJ, Brookmeyer R: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347–1353, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Antman K, Bearman SI, Davidson N, deVries E, Gianni AM, Gisselbrecht C, Lazarus HM, Livingston RB, Maraninchi D, McElwain TJ, Ogawa M, Rost G, Slease RB, Spitzer G, Tajima T, Vaughan WP, Williams S: Dose intensive therapy in breast cancer: Current Status. In Gale RP, Champlin RE (eds): New strategies in bone marrow transplantation (New series on molecular & cellular biology). New York: Alan R. Liss, in press.Google Scholar
  12. 12.
    Clark GM, Sledge GW, Osborne CK: Survival from first recurrence: Relative importance of prognostic factors of 1105 breast cancer patients. J Clin Oncol 5:55–61, 1987.PubMedGoogle Scholar
  13. 13.
    Ahmann FR, Jones SE, Moon TE: The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 37:116–122, 1988.PubMedCrossRefGoogle Scholar
  14. 14.
    Falkson G, Gelman RS, Tormey DC: Treatment of metastatic breast cancer in pre-menopausal women using CAF with or without oophorectomy: An Eastern Cooperative Oncology Group study. J Clin Oncol 5:881–889, 1987.PubMedGoogle Scholar
  15. 15.
    Peters WP, Shpall EJ, Jones RB: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1376, 1990.Google Scholar
  16. 16.
    Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy metastatic breast cancer. J Natl Cancer Inst 83:920–926, 1991.PubMedCrossRefGoogle Scholar
  17. 17.
    Williams S, Gilewski T, Mick R, Bitran JD: High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743–1747, 1992.PubMedGoogle Scholar
  18. 18.
    Antman K, Ayash L, Elias A, et al.: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102–110, 1992.PubMedGoogle Scholar
  19. 19.
    Dunphy FR, Spitzer G, Rossiter Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortabagyi GN: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73:2157–2167, 1994.PubMedCrossRefGoogle Scholar
  20. 20.
    Jones RB, Shpall EJ, Ross M, Bass R, Affronti M, Peters WP: AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support for advanced breast cancer, current results (abstr). Proc Am Soc Clin Oncol 9:9, 1990.Google Scholar
  21. 21.
    Peters WP: Autologous bone marrow transplantation in primary breast cancer: The American experience. Submitted for publication, 1994.Google Scholar
  22. 22.
    Maranichi D, Piana L, Blaise DET: Phase I—II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In Autologous bone marrow transplantation. Proceedings of the 3rd International Symposium. University of Texas MD Anderson Hospital, Houston, TX, 1987.Google Scholar
  23. 23.
    Lemaistre CF, Herqig GP, Herqig RH: High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer. Breast Cancer Res Treat 10:89, 1987.Google Scholar
  24. 24.
    Lazarus HM, Herzig RH, Graham-Pole J: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359–367, 1983.PubMedGoogle Scholar
  25. 25.
    Wolff SN, Herzig RH, Fay JW: High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol 17:2–6, 1990.PubMedGoogle Scholar
  26. 26.
    Eder JP, Antman K, Peters W: High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4:1592–1597, 1986.PubMedGoogle Scholar
  27. 27.
    Eder JP, Antman K, Elias A: Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 80:1221–1226.Google Scholar
  28. 28.
    Moormeier JA, Williams SF, Kaminer LS, Garner M, Bitran JD: High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst 82:29–34, 1990.PubMedCrossRefGoogle Scholar
  29. 29.
    Eder JP, Elias A, Shea TC: A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 8:1239–1245, 1990.PubMedGoogle Scholar
  30. 30.
    Triozzi PL: Autologous bone marrow and peripheral blood progenitor transplant for breast cancer. Lancet 344:418–419, 1994.PubMedCrossRefGoogle Scholar
  31. 31.
    Eddy DM: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10:657–6701, 1992.PubMedGoogle Scholar
  32. 32.
    Henderson IC: Window of opportunity. J Natl Cancer Inst 83:894–896, 1991.PubMedCrossRefGoogle Scholar
  33. 33.
    West WH, Birch R, Schwartzberg LS, Tauer KW, Kaiman LA, Altemose RW, Weaver CH: High-dose cyclophosphamide, thiotepa and carboplatin in advanced breast cancer: Clinical features predictive of outcome. 1994, submitted for publication.Google Scholar
  34. 34.
    Cox DR: Regression models and life-tables. J R Stat Soc, Ser B 34:187–202, 1972.Google Scholar
  35. 35.
    The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 8:563–564, 1990.Google Scholar
  36. 36.
    Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757–765, 1986.PubMedGoogle Scholar
  37. 37.
    Dunphy FR, Spitzer G, Buzdor AU: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207–1216, 1990.PubMedGoogle Scholar
  38. 38.
    Bearman SI, Stemmer SM, Jones RB, Shpall EJ, Myers SE: High-dose chemotherapy with autologous progenitor support for stage IV breast cancer in patients with osseous metastatses only or without measurable disease (abstr). Proc Am Soc Clin Oncol 12:106, 1993.Google Scholar
  39. 39.
    Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, Rowley S, Benyunes K, Chauncey T, Fefer A, Hackman R, Gooley T, Schiffman K, Storb R, Sullivan KM, Weiden P, Witherspoon R, Buckner CD: High dose fractionated total body irradiation, etoposide and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol 12:2559–2566, 1994.PubMedGoogle Scholar
  40. 40.
    Petersen FB, Lynch MHE, Clift RA: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 11:1353–1360, 1993.PubMedGoogle Scholar
  41. 41.
    Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Hill R, Mortimer J, Neiman PE, Sanders JE, Singer J, Stewart P, Storb R, Thomas ED: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340–1347, 1987.PubMedGoogle Scholar
  42. 42.
    Peters WP, Ross M, Vredenbugh JJ: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132–1143, 1993.PubMedGoogle Scholar
  43. 43.
    Gianni AM, Siena S, Bregni M: Growth-factor supported high-dose sequential adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Proc Am Soc Clin Oncol 11:61, 1992.Google Scholar
  44. 44.
    Schwartzberg L, Birch R, Hazelton B, Tauer K, Kaiman L, Ross A, Raefsky E, Wittlin F, Schnell F, West W: High-dose chemotherapy with peripheral blood stem cell (PBSC) support for high risk stage II and stage III breast cancer. Proc Am Soc Clin Oncol 13:97 (Abstr.), 1994, in press.Google Scholar
  45. 45.
    Bensinger WI, personal communication.Google Scholar
  46. 46.
    Clark JG, Hansen JA, Hertz MI: Idiopathic pneumonia syndrome following bone marrow transplantation. Am Rev Respir Dis 147:1601–1606, 1993.PubMedGoogle Scholar
  47. 47.
    Nemunaitis J, Singer JW, Buckner CD: Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 72:834–836, 1988.PubMedGoogle Scholar
  48. 48.
    Linch DC, Scarffe H, Proctor S: Randomized vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11:307–311, 1993.PubMedGoogle Scholar
  49. 49.
    Nemunaitis J: Role of GM-CSF and G-CSF in stem cell transplantation. Oncology 7: 27–32, 1993.Google Scholar
  50. 50.
    Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenberg DD: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–727, 1988.PubMedGoogle Scholar
  51. 51.
    Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, West W: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 11:369–374, 1993.PubMedGoogle Scholar
  52. 52.
    Bensinger WI, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clark E, Clift R, Hansen J, Shieds T, Storb R, Weaver CH, Weiden P, Buckner CD: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158–3163, 1993.PubMedGoogle Scholar
  53. 53.
    Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1:640–644, 1992.CrossRefGoogle Scholar
  54. 54.
    Williams SF, Bitran JD, Richards JM, DeChristopher PJ, Barker E, Conant J, Golomb HM, Orlina AR: Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: An alternative approach. Bone Marrow Transplant 5:123–133, 1990.Google Scholar
  55. 55.
    Schwartzberg L, Birch R, Heffernan M, West W: G-CSF in an effective supportive modality in peripheral blood stem cell (PBSC) transplantation. Blood 82:286a, 1993.Google Scholar
  56. 56.
    Spitzer G, Spencer V, Dunphy F, Kulkarni S, Petruska P, Velasuez W, Ruppel L, Adkins D: Are growth factors (GF) needed after peripheral blood stem cell (PBSC) transplantation? A randomized study to evaluate the question. Proc Am Soc Clin Oncol 12: 467 (Abstr.), 1993.Google Scholar
  57. 57.
    Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825–831, 1994.PubMedCrossRefGoogle Scholar
  58. 58.
    Brenner MK, Rill RD, Moen RC, Kranee RA, Mirro J, Anderson MFO, Ihle WF: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85–86, 1993.PubMedCrossRefGoogle Scholar
  59. 59.
    Deisseroth AB, Zu Z, Claxton D, Hanania EG, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Calvert L, Tibbits P, Talpaz M, Kanterjian H, Champlin R, Reading C: Genetic marking shows that PH+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation. Blood 83:3068–3076, 1994.PubMedGoogle Scholar
  60. 60.
    Peters WP, Petross WP, Guppton C, Vredenburgh JJ, Hussein A, Ross M, Rubin P, Elkordy M, Affronti ML, Moore S: The effect of induction chemotherapy dose intensity on complete response frequency in early metastatic breast cancer. Proc Am Soc Clin Oncol 13:87 (Abstr.), 1994.Google Scholar
  61. 61.
    Pagani O, Sessa A, Goldhirsch A, Cavilli F: Taxol and cyclophosphamide in patients with advanced breast cancer: A dose-finding study with the addition of G-CSF. Proc Am Soc Clin Oncol 13:61, 1994.Google Scholar
  62. 62.
    Tolcher A, Cowan K, Riley J, Kohler D, Goldspiel B, Denicoff A, McCabe M, Soloman D, Gossard M, Noone M, O’Shaughnessy J: Phase I study of paclitaxel and cyclophosphamide and G-CSF in metastatic breast cancer. Proc Am Soc Clin Oncol 13:73, 1994.Google Scholar
  63. 63.
    Alter R, Speyer J, Hochster H, Oratz R, Wernz J, Chachoua A, Meyers M, Sorich J, Downey A, Friedberg A, Blum R: Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer. Proc Am Soc Clin Oncol 13:100, 1994.Google Scholar
  64. 64.
    Gelmon KA, O’Reilley S, Plendderleith IH, Bryce C, Ragaz J, Coppin C, Campbell C, Healy D, Onetto N: Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 13:71, 1994.Google Scholar
  65. 65.
    Bierman P, Anderson J, Vose J, Freeman M, Bishop M, Kesinger A, Armitage J: High-dose chemotherapy with autologous hematopoietic rescue for Hodgkin’s disease (HD) following first relapse after chemotherapy. Proc Am Soc Clin Oncol 12:366 (Abstr.), 1993.Google Scholar
  66. 66.
    Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI, Sanders J, Sullivan KM, Storb R, Singer J, Hansen JA, Thomas ED: Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10: 1723–1729, 1992.PubMedGoogle Scholar
  67. 67.
    Klumpp TR, Mangan KF, Glenn LD, MacDonald JS: Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 11: 337–339, 1993.PubMedGoogle Scholar
  68. 68.
    Chabner BA, Collins M: Cancer Chemotherapy: Principles and Practice. Philadelphia: Lippincott, 1990, p 278.Google Scholar
  69. 69.
    Weaver CH, Bensinger WI, Appelbaum K, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Trueblood K, Klarnet J, Buckner CD: A phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant, 1994, in press.Google Scholar
  70. 70.
    Crown J, Raptis G, Vadat L, Fenelly D, Hamilton N, Hudis C, Gilewski T, Seidman A, Reich L, Norton L: Rapid administration of sequential high-dose (HD) cyclophosphamide (CPA), melphalan (M), thiotepa (TT) supported filgrastim (G) + peripheral blood progenitors (PBP) in patients (PTS) with metastatic breast cancer (MBC): A novel and very active treatment strategy. Proc Am Soc Clin Oncol 13:110 (Abstr.), 1994.Google Scholar
  71. 71.
    Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ: Ifosfamide carboplatin and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol 12: 544–552, 1994.PubMedGoogle Scholar
  72. 72.
    Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL: High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689–695, 1987.PubMedGoogle Scholar
  73. 73.
    Farber S, Appleton R, Downing V: Clinical studies on the carcinolytic action of triethy-lenephosphoramide. Cancer 6:135–141, 1953.CrossRefGoogle Scholar
  74. 74.
    Corringham R, Gilmore M, Prentice H: High-dose melphalan with autologous bone marrow transplant: Treatment of poor prognosis tumors. Cancer 52:1783–1787, 1983.PubMedCrossRefGoogle Scholar
  75. 75.
    Bateman JC, Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med 252:879–887, 1955.PubMedCrossRefGoogle Scholar
  76. 76.
    Ultmann JE, Hyman GA, Crandall C: Triethylenephosphoramide (thio-TEPA) in the treatment of neoplastic disease. Cancer 10:902–911, 1957.PubMedCrossRefGoogle Scholar
  77. 77.
    Frei EI, Cucchi GA, Rosowski A: Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158–2162, 1985.PubMedCrossRefGoogle Scholar
  78. 78.
    Bitran J, Williams S, Robin E: High-dose trialkylator chemotherapy (TACT) with thiotepa (TT), cytoxan and oral melphalan and autologous stem cell rescue (ASCR) in patients with disseminated cancer. Proc Am Soc Clin Oncol 7:46, 1988.Google Scholar
  79. 79.
    Ayash LJ, Elias A, Wheeler C: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37–44, 1994.PubMedGoogle Scholar
  80. 80.
    Crown J, Fenelly D, Schneider J, Hakes T, Bengala C, McKenzie M, Reich L, Barakat R, Curtin J, Spriggs D, Hoskins W, Norton L: Escalating dose toxol (T) + high-dose (HD) cyclophosphamide (C)/G-CSF(G) as induction and to mobilize peripheral blood progenitors (PBP) for use as rescue following multiple courses of HD carboplatin (P)/C: A phase I trial in ovarian cancer patients (PTS). Proc Am Soc Clin Oncol 13:262(Abstr.), 1994.Google Scholar
  81. 81.
    Ghalie R, Richman C, Bender J, McLoed B, Lee W, Manson S, Van Epps D, Valentino L, Feingold J, Pruett J, Brown S, Kaizer H: Tandem transplants using peripheral blood progenitor cells (PBSC) mobilized with chemotherapy and filgrastim (G-CSF). Proc Am Soc Clin Oncol 13:435 (Abstr.), 1994.Google Scholar
  82. 82.
    Bitran JD, Stone LA, Bennett CL: Autologous BMT vs. mobilized peripheral blood progenitor cells in breast cancer. Oncology 7(Suppl):33–36, 1993.Google Scholar
  83. 83.
    To LB, Robers MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQK, Dart GW, Harvoth N, Davy MLJ, Olweny CLM, Abdi E, Juttner CA: Comparison of hemato-logical recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277–284, 1992.PubMedGoogle Scholar
  84. 84.
    Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W: Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 18:94–98, 1990.PubMedGoogle Scholar
  85. 85.
    Hohaus S, Goldschmidt H, Ehrhardt R, Haas R: Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508–514, 1993.PubMedGoogle Scholar
  86. 86.
    Kessinger A, Smith DM, Strandford SE, Landmark JD, Dooley DC, Law P, Coccia PF, Warkentin PI, Weisenburger DD, Armitage JO: Allogeneic transplantation of blood-derived, T-cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 4:643, 1989.PubMedGoogle Scholar
  87. 87.
    Russel NH, Hunter A, Rogers S, Hanley J, Anderson D: Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 341:1482, 1993.CrossRefGoogle Scholar
  88. 88.
    Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749–1756, 1991.PubMedGoogle Scholar
  89. 89.
    Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cell in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol 10:1534–1539, 1992.PubMedGoogle Scholar
  90. 90.
    Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475–482, 1994.PubMedGoogle Scholar
  91. 91.
    Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM: Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer 63:2509–2514, 1989.PubMedCrossRefGoogle Scholar
  92. 92.
    Redding WH, Monoghan P, Imrie SF: Detection of micrometastases in patients with primary breast cancer. Lancet 2:1271–1274, 1983.PubMedCrossRefGoogle Scholar
  93. 93.
    Mann SL, Joshi SS, Weisenburger DD: Detection of tumor cells in histological normal bone marrow of autologous transplant patients using culture techniques. Exp Hematol 14:54, 1986.Google Scholar
  94. 94.
    Sharp JC, Kessinger A, Mann S, Crouse D, Dicke JA, Masih A, Weisenberger DD: Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 10:92, 1992.CrossRefGoogle Scholar
  95. 95.
    Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic cells into peripheral blood of patients with solid tumors. Blood 83:636–640, 1994.PubMedGoogle Scholar
  96. 96.
    Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Swet D, Winter C, Akard L, Jansen J, Copellan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immuno-cytochemical and clonogenic assay techniques. Blood 82:2605–2610, 1993.PubMedGoogle Scholar
  97. 97.
    Vredenburgh JJ, Ross M, Hussein A, Bast RC, Jr, Shpall EJ, Tyer C, Peters WP: High-dose chemotherapy and purged autologous bone marrow support for patients with metastatic breast cancer. 23rd Annual Keystone Symposia. 1994.Google Scholar
  98. 98.
    Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallogan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28–36, 1994.PubMedGoogle Scholar
  99. 99.
    Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 11:2187–2190, 1990.Google Scholar
  100. 100.
    Mazumder A, Verma U, Areman E, Rajagopal C, Cahill R, Swain S: Peripheral blood stem cell (PBSC) transplantation in breast cancer patients with interleukin-2 (IL-2) activated PBSC leads to visceral graft vs host disease (GVHD). Proc Am Soc Clin Oncol 13:72, 1994.Google Scholar
  101. 101.
    Cunningham D, Powles R, Malpas R, Milan JS, Meldrum S, Viner M, Montes C, Hickish A, Nicolson T, Johnson M, Mansi P, Treleaven J, Raymond J, Gore ME: A randomized trial of maintenance therapy into intron-A following high-dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 12:364, 1993.Google Scholar
  102. 102.
    Higano CS, Raskind WH, Singer JW: Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437–1442, 1992.PubMedGoogle Scholar
  103. 103.
    Ding L, Lalini EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PYS, Taylor-Papadimitriou J, Longenecker BM: Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene:Effect of immunization on the growth of murine mammary adenocarcinoma cells trans-fected with the human MUC1 gene. Cancer Immunol Immunother 36:9–17, 1993.PubMedCrossRefGoogle Scholar
  104. 104.
    MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM: Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292–305, 1992.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Charles H. Weaver
  • Robert Birch
  • Lee S. Schwartzberg
  • William H. West

There are no affiliations available

Personalised recommendations